Expanded Criteria Donors

Clinics in Liver Disease

Volumn 18, Issue 3, 2014, Pages 633-649

  Feng, Sandy ^a   Lai, Jennifer C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Deceased donor; Donor age; Outcomes; Steatosis; Surgery

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN;

COLD ISCHEMIA; DISEASE CONTROL; DISEASE TRANSMISSION; DONOR SELECTION; FATTY LIVER; GRAFT DYSFUNCTION; GROUPS BY AGE; HEART DEATH; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; NEOPLASM; ORGAN DONOR; REVIEW; RISK FACTOR; VIRUS HEPATITIS; ADOLESCENT; ADULT; ADVERSE EFFECTS; AGE; AGED; CHILD; DEATH; DONOR; GRAFT SURVIVAL; LIVER TRANSPLANTATION; MIDDLE AGED; PATHOLOGY; PROGNOSIS; TRANSMISSION; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; CHILD; DEATH; DONOR SELECTION; FATTY LIVER; GRAFT SURVIVAL; HEPATITIS, VIRAL, HUMAN; HIV INFECTIONS; HUMANS; LIVER TRANSPLANTATION; MIDDLE AGED; NEOPLASMS; PROGNOSIS; RISK FACTORS; TISSUE DONORS; YOUNG ADULT;

EID: 84903987126     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2014.05.005     Document Type: Review

References (120)

1. Schmucker D.L. Aging and the liver: an update. JGerontol A Biol Sci Med Sci 1998, 53(5):B315-B320.
2. Kim D.Y., Moon J., Island E.R., et al. Liver transplantation using elderly donors: a risk factor analysis. Clin Transplant 2011, 25(2):270-276.
3. Feng S., Goodrich N., Bragg-Gresham J., et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 2006, 6(4):783-790.
4. Hoofnagle J.H., Lombardero M., Zetterman R.K., et al. Donor age and outcome after liver transplantation. Hepatology 1996, 24(1):89-96.
5. Washburn W.K., Johnson L.B., Lewis W.D., et al. Graft function and outcome of older (> or= 60 years) donor livers. Transplantation 1996, 61(7):1062-1066.
6. Singhal A., Sezginsoy B., Ghuloom A.E., et al. Orthotopic liver transplant using allografts from geriatric population in the United States: is there any age limit?. Exp Clin Transplant 2010, 8(3):196-201.
7. Busquets J., Xiol X., Figueras J., et al. The impact of donor age on liver transplantation: influence of donor age on early liver function and on subsequent patient and graft survival. Transplantation 2001, 71(12):1765-1771.
8. Nardo B., Masetti M., Urbani L., et al. Liver transplantation from donors aged 80years and over: pushing the limit. Am J Transplant 2004, 4(7):1139-1147.
9. Marino I.R., Doyle H.R., Aldrighetti L., et al. Effect of donor age and sex on the outcome of liver transplantation. Hepatology 1995, 22(6):1754-1762.
10. Lake J.R., Shorr J.S., Steffen B.J., et al. Differential effects of donor age in liver transplant recipients infected with hepatitis B, hepatitis C and without viral hepatitis. Am J Transplant 2005, 5(3):549-557.
11. Moore D.E., Feurer I.D., Speroff T., et al. Impact of donor, technical, and recipient risk factors on survival and quality of life after liver transplantation. Arch Surg 2005, 140(3):273-277.
12. Lai J.C., Vittinghoff E., Feng S. The evolving face of liver donors in the United States: updating the donor risk index. Am J Transplant 2013, 13(S5). [abstract: 188].
13. Park Y., Hirose R., Coatney J.L., et al. Ischemia-reperfusion injury is more severe in older versus young rat livers. JSurg Res 2007, 137(1):96-102.
14. Okaya T., Blanchard J., Schuster R., et al. Age-dependent responses to hepatic ischemia/reperfusion injury. Shock 2005, 24(5):421-427.
15. Jiménez-Romero C., Clemares-Lama M., Manrique-Municio A., et al. Long-term results using old liver grafts for transplantation: sexagenerian versus liver donors older than 70 years. World J Surg 2013, 37(9):2211-2221.
16. Grazi G.L., Cescon M., Ravaioli M., et al. Arevised consideration on the use of very aged donors for liver transplantation. Am J Transplant 2001, 1(1):61-68.
17. Ploeg R.J., D'Alessandro A.M., Knechtle S.J., et al. Risk factors for primary dysfunction after liver transplantation-a multivariate analysis. Transplantation 1993, 55(4):807-813.
18. Strasberg S.M., Howard T.K., Molmenti E.P., et al. Selecting the donor liver: risk factors for poor function after orthotopic liver transplantation. Hepatology 1994, 20(4 Pt 1):829-838.
19. Uemura T., Nikkel L.E., Hollenbeak C.S., et al. How can we utilize livers from advanced aged donors for liver transplantation for hepatitis C?. Transpl Int 2012, 25(6):671-679.
20. Wall W.J., Mimeault R., Grant D.R., et al. The use of older donor livers for hepatic transplantation. Transplantation 1990, 49(2):377-381.
21. DeBakey M.E., Lawrie G.M., Glaeser D.H. Patterns of atherosclerosis and their surgical significance. Ann Surg 1985, 201(2):115-131.
22. Showstack J., Katz P.P., Lake J.R., et al. Resource utilization in liver transplantation: effects of patient characteristics and clinical practice. NIDDK Liver Transplantation Database Group. JAMA 1999, 281(15):1381-1386.
23. Salvalaggio P.R., Dzebisashvili N., MacLeod K.E., et al. The interaction among donor characteristics, severity of liver disease, and the cost of liver transplantation. Liver Transpl 2011, 17(3):233-242.
24. Axelrod D.A., Gheorghian A., Schnitzler M.A., et al. The economic implications of broader sharing of liver allografts. Am J Transplant 2011, 11(4):798-807.
25. Cescon M., Grazi G.L., Ercolani G., et al. Long-term survival of recipients of liver grafts from donors older than 80 years: is it achievable?. Liver Transpl 2003, 9(11):1174-1180.
26. Ghobrial R.M., Gornbein J., Steadman R., et al. Pretransplant model to predict posttransplant survival in liver transplant patients. Ann Surg 2002, 236(3):315-322. [discussion: 322-3].
27. Lai J.C., O'Leary J.G., Trotter J.F., et al. Risk of advanced fibrosis with grafts from hepatitis C antibody-positive donors: a multicenter cohort study. Liver Transpl 2012, 18(5):532-538.
28. Shores N.J., Dodge J.L., Feng S., et al. Donor risk index for African American liver transplant recipients with hepatitis C virus. Hepatology 2013, 58(4):1263-1269.
29. Lai J.C., Verna E.C., Brown R.S., et al. Hepatitis C virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men. Hepatology 2011, 54(2):418-424.
30. Wali M., Harrison R.F., Gow P.J., et al. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 2002, 51(2):248-252.
31. Khapra A.P., Agarwal K., Fiel M.I., et al. Impact of donor age on survival and fibrosis progression in patients with hepatitis C undergoing liver transplantation using HCV+ allografts. Liver Transpl 2006, 12(10):1496-1503.
32. Alonso O., Loinaz C., Moreno E., et al. Advanced donor age increases the risk of severe recurrent hepatitis C after liver transplantation. Transpl Int 2005, 18(8):902-907.
33. Samonakis D.N., Triantos C.K., Thalheimer U., et al. Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation. Liver Transpl 2005, 11(4):386-395.
34. Thuluvath P.J., Guidinger M.K., Fung J.J., et al. Liver transplantation in the United States, 1999-2008. Am J Transplant 2010, 10(4 Pt 2):1003-1019.
35. Lai J.C., Vittinghoff E., Feng S. The evolving face of the liver donor: updating the donor risk index [abstract]. Am J Transplant 2013, 13(S5):4-589.
36. Sela N., Croome K.P., Chandok N., et al. Changing donor characteristics in liver transplantation over the last 10 years in Canada. Liver Transpl 2013, 19(11):1236-1244.
37. Adam R., Karam V., Delvart V., et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry(ELTR). JHepatol 2012, 57(3):675-688.
38. Halldorson J., Roberts J.P. Decadal analysis of deceased organ donation in Spain and the United States linking an increased donation rate and the utilization of older donors. Liver Transpl 2013, 19(9):981-986.
39. Ravaioli M., Grazi G.L., Cescon M., et al. Liver transplantations with donors aged 60 years and above: the low liver damage strategy. Transpl Int 2009, 22(4):423-433.
40. Jay C.L., Lyuksemburg V., Ladner D.P., et al. Ischemic cholangiopathy after controlled donation after cardiac death liver transplantation. Ann Surg 2011, 253(2):259-264.
41. Abt P.L., Desai N.M., Crawford M.D., et al. Survival following liver transplantation from non-heart-beating donors. Ann Surg 2004, 239(1):87-92.
42. Chan E.Y., Olson L.C., Kisthard J.A., et al. Ischemic cholangiopathy following liver transplantation from donation after cardiac death donors. Liver Transpl 2008, 14(5):604-610.
43. de Vera M.E., Lopez-Solis R., Dvorchik I., et al. Liver transplantation using donation after cardiac death donors: long-term follow-up from a single center. Am J Transplant 2009, 9(4):773-781.
44. Foley D.P., Fernandez L.A., Leverson G., et al. Donation after cardiac death. Ann Surg 2005, 242(5):724-731.
45. Fujita S., Mizuno S., Fujikawa T., et al. Liver transplantation from donation after cardiac death: a single center experience. Transplantation 2007, 84(1):46-49.
46. Manzarbeitia C.Y., Ortiz J.A., Jeon H., et al. Long-term outcome of controlled, non-heart-beating donor liver transplantation. Transplantation 2004, 78(2):211-215.
47. Grewal H.P., Willingham D.L., Nguyen J., et al. Liver transplantation using controlled donation after cardiac death donors: an analysis of a large single-center experience. Liver Transpl 2009, 15(9):1028-1035.
48. Pine J.K., Aldouri A., Young A.L., et al. Liver transplantation following donation after cardiac death: an analysis using matched pairs. Liver Transpl 2009, 15(9):1072-1082.
49. Skaro A.I., Jay C.L., Baker T.B., et al. The impact of ischemic cholangiopathy in liver transplantation using donors after cardiac death: the untold story. Surgery 2009, 146(4):543-553.
50. Merion R.M., Pelletier S.J., Goodrich N., et al. Donation after cardiac death as a strategy to increase deceased donor liver availability. Trans Meet Am Surg Assoc Am Surg Assoc 2006, 124:220-227.
51. Mateo R., Cho Y., Singh G., et al. Risk factors for graft survival after liver transplantation from donation after cardiac death donors: an analysis of OPTN/UNOS data. Am J Transplant 2006, 6(4):791-796.
52. Vanatta J.M., Dean A.G., Hathaway D.K., et al. Liver transplant using donors after cardiac death: a single-center approach providing outcomes comparable to donation after brain death. Exp Clin Transplant 2013, 11(2):154-163.
53. Hong J.C., Yersiz H., Kositamongkol P., et al. Liver transplantation using organ donation after cardiac death: a clinical predictive index for graft failure-free survival. Arch Surg 2011, 146(9):1017-1023.
54. Jay C.L., Skaro A.I., Ladner D.P., et al. Comparative effectiveness of donation after cardiac death versus donation after brain death liver transplantation: recognizing who can benefit. Liver Transpl 2012, 18(6):630-640.
55. Selzner N., Selzner M., Jochum W., et al. Mouse livers with macrosteatosis are more susceptible to normothermic ischemic injury than those with microsteatosis. JHepatol 2006, 44(4):694-701.
56. Berthiaume F., Barbe L., Mokuno Y., et al. Steatosis reversibly increases hepatocyte sensitivity to hypoxia-reoxygenation injury. JSurg Res 2009, 152(1):54-60.
57. Taneja C., Prescott L., Koneru B. Critical preservation injury in rat fatty liver is to hepatocytes, not sinusoidal lining cells. Transplantation 1998, 65(2):167-172.
58. Teramoto K., Bowers J.L., Kruskal J.B., et al. Hepatic microcirculatory changes after reperfusion in fatty and normal liver transplantation in the rat. Transplantation 1993, 56(5):1076-1082.
59. Fukumori T., Ohkohchi N., Tsukamoto S., et al. The mechanism of injury in a steatotic liver graft during cold preservation. Transplantation 1999, 67(2):195-200.
60. Caraceni P., Bianchi C., Domenicali M., et al. Impairment of mitochondrial oxidative phosphorylation in rat fatty liver exposed to preservation-reperfusion injury. JHepatol 2004, 41(1):82-88.
61. Chalasani N., Younossi Z., Lavine J.E., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012, 55(6):2005-2023.
62. Marchesini G., Brizi M., Bianchi G., et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001, 50(8):1844-1850.
63. Day C.P., Saksena S. Non-alcoholic steatohepatitis: definitions and pathogenesis. JGastroenterol Hepatol 2002, 17(Suppl 3):S377-S384.
64. Sanyal A.J. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002, 123(5):1705-1725.
65. Marchesini G. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003, 37(4):917-923.
66. Ahn J.S., Sinn D.H., Gwak G.Y., et al. Steatosis among living liver donors without evidence of fatty liver on ultrasonography. Transplantation 2013, 95(11):1404-1409.
67. de Graaf E.L., Kench J., Dilworth P., et al. Grade of deceased donor liver macrovesicular steatosis impacts graft and recipient outcomes more than the donor risk index. JGastroenterol Hepatol 2012, 27(3):540-546.
68. Dutkowski P., Schlegel A., Slankamenac K., et al. The use of fatty liver grafts in modern allocation systems. Ann Surg 2012, 256(5):861-869.
69. Chavin K.D., Taber D.J., Norcross M., et al. Safe use of highly steatotic livers by utilizing a donor/recipient clinical algorithm. Clin Transplant 2013, 27:732-741.
70. Gabrielli M., Moisan F., Vidal M., et al. Steatotic livers. Can we use them in OLTX? Outcome data from a prospective baseline liver biopsy study. Ann Hepatol 2012, 11(6):891-898.
71. McCormack L., Petrowsky H., Jochum W., et al. Use of severely steatotic grafts in liver transplantation. Ann Surg 2007, 246(6):940-948.
72. Spitzer A.L., Lao O.B., Dick A.A., et al. The biopsied donor liver: incorporating macrosteatosis into high-risk donor assessment. Liver Transpl 2010, 16(7):874-884.
73. Lee S.W., Park S.H., Kim K.W., et al. Unenhanced CT for assessment of macrovesicular hepatic steatosis in living liver donors: comparison of visual grading with liver attenuation index 1. Radiology 2007, 244(2):479-485.
74. Franzén L.E., Ekstedt M., Kechagias S., et al. Semiquantitative evaluation overestimates the degree of steatosis in liver biopsies: a comparison to stereological point counting. Mod Pathol 2005, 18(7):912-916.
75. Brunt E.M. Histopathology of nonalcoholic fatty liver disease. World J Gastroenterol 2010, 16(42):5286.
76. Silberhumer G.R., Rahmel A., Karam V., et al. The difficulty in defining extended donor criteria for liver grafts: the Eurotransplant experience. Transpl Int 2013, 26(10):990-998.
77. Burroughs A.K., Sabin C.A., Rolles K., et al. 3-month and 12-month mortality after first liver transplant in adults in Europe: predictive models for outcome. Lancet 2006, 367(9506):225-232.
78. Guichelaar M.M., Benson J.T., Malinchoc M., et al. Risk factors for and clinical course of non-anastomotic biliary strictures after liver transplantation. Am J Transplant 2003, 3(7):885-890.
79. Brunner S.M., Junger H., Ruemmele P., et al. Bile duct damage after cold storage of deceased donor livers predicts biliary complications after liver transplantation. JHepatol 2013, 58(6):1133-1139.
80. Van Thiel D.H., De Maria N., Colantoni A., et al. Can hepatitis B core antibody positive livers be used safely for transplantation: hepatitis B virus detection in the liver of individuals who are hepatitis B core antibody positive. Transplantation 1999, 68(4):519-522.
81. Suehiro T., Shimada M., Kishikawa K., et al. Prevention of hepatitis B virus infection from hepatitis B core antibody-positive donor graft using hepatitis B immune globulin and lamivudine in living donor liver transplantation. Liver Int 2005, 25(6):1169-1174.
82. Prieto M., Gomez M.D., Berenguer M., et al. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. Liver Transpl 2001, 7(1):51-58.
83. Roque-Afonso A.M., Feray C., Samuel D., et al. Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors. Gut 2002, 50(1):95-99.
84. Angelico M., Nardi A., Marianelli T., et al. Hepatitis B-core antibody positive donors in liver transplantation and their impact on graft survival: evidence from the LiverMatch cohort study. JHepatol 2013, 58(4):715-723.
85. Lee K.H., Wai C.T., Lim S.G., et al. Risk for de novo hepatitis B from antibody to hepatitis B core antigen-positive donors in liver transplantation in Singapore. Liver Transpl 2001, 7(5):469-470.
86. Chen Y.S., Wang C.C., de Villa V.H., et al. Prevention of de novo hepatitis B virus infection in living donor liver transplantation using hepatitis B core antibody positive donors. Clin Transplant 2002, 16(6):405-409.
87. Cholongitas E., Papatheodoridis G.V., Burroughs A.K. Liver grafts from anti-hepatitis B core positive donors: a systematic review. JHepatol 2010, 52(2):272-279.
88. Skagen C.L., Jou J.H., Said A. Risk of de novo hepatitis in liver recipients from hepatitis-B core antibody-positive grafts - a systematic analysis. Clinical Transplantation 2011, 25(3):E243-E249.
89. Manzarbeitia C. Safe use of livers from donors with positive hepatitis B core antibody. Liver Transpl 2002, 8(6):556-561.
90. Yu A.S., Vierling J.M., Colquhoun S.D., et al. Transmission of hepatitis B infection from hepatitis B core antibody-positive liver allografts is prevented by lamivudine therapy. Liver Transpl 2001, 7(6):513-517.
91. Joya-Vazquez P.P., Dodson F.S., Dvorchik I., et al. Impact of anti-hepatitis Bc-positive grafts on the outcome of liver transplantation for HBV-related cirrhosis. Transplantation 2002, 73(10):1598-1602.
92. Nery J.R., Nery-Avila C., Reddy K.R., et al. Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudine. Transplantation 2003, 75(8):1179-1186.
93. Montalti R., Nardo B., Bertelli R., et al. Donor pool expansion in liver transplantation. Transplant Proc 2004, 36(3):520-522.
94. Donataccio D., Roggen F., Reyck C., et al. Use of anti-HBc positive allografts in adult liver transplantation: toward a safer way to expand the donor pool. Transpl Int 2006, 19(1):38-43.
95. Prakoso E., Strasser S.I., Koorey D.J., et al. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors. Clin Transplant 2006, 20(3):369-373.
96. Cheung C.K.Y., Lo C.M., Man K., et al. Occult hepatitis B virus infection of donor and recipient origin after liver transplantation despite nucleoside analogue prophylaxis. Liver Transpl 2010, 16(11):1314-1323.
97. Yu L., Koepsell T., Manhart L., et al. Survival after orthotopic liver transplantation: the impact of antibody against hepatitis B core antigen in the donor. Liver Transpl 2009, 15(10):1343-1350.
98. Choi Y., Choi J.Y., Yi N.J., et al. Liver transplantation for HBsAg-positive recipients using grafts from HBsAg-positive deceased donors. Transpl Int 2013, 26(12):1173-1183.
99. Northup P.G., Argo C.K., Nguyen D.T., et al. Liver allografts from hepatitis C positive donors can offer good outcomes in hepatitis C positive recipients: a US National Transplant Registry analysis. Transpl Int 2010, 23(10):1038-1044.
100. Burr A.T., Li Y., Tseng J.F., et al. Survival after liver transplantation using hepatitis C virus-positive donor allografts: case-controlled analysis of the UNOS database. World J Surg 2011, 35(7):1590-1595.
101. Ballarin R., Montalti R., Spaggiari M., et al. Liver transplantation in older adults: our point of view. JAm Geriatr Soc 2011, 59(7):1359-1361.
102. HIV Organ Policy Equity Act [Internet]. thomas.loc.gov. [cited May 1, 2013]. Available at: Accessed April 5, 2013. http://thomas.loc.gov/cgi-bin/query/z?c113:H.R.698.
103. Boyarsky B.J., Hall E.C., Singer A.L., et al. Estimating the potential pool of HIV-infected deceased organ donors in the United States. Am J Transplant 2011, 11(6):1209-1217.
104. Mgbako O., Glazier A., Blumberg E., et al. Allowing HIV-positive organ donation: ethical, legal and operational considerations. Am J Transplant 2013, 13(7):1636-1642.
105. CDC CDC guidelines for preventing transmission of human immunodeficiency virus through transplantation of human tissue and organs. MMWR Morb Mortal Wkly Rep 1994, 43:1-26.
106. Kucirka L.M., Alexander C., Namuyinga R., et al. Viral nucleic acid testing (NAT) and OPO-level disposition of high-risk donor organs. Am J Transplant 2009, 9(3):620-628.
107. Ellingson K., Seem D., Nowicki M., for the Organ Procurement Organization Nucleic Acid Testing Yield Project Team, et al. Estimated risk of human immunodeficiency virus and hepatitis C virus infection among potential organ donors from 17 organ procurement organizations in the United States. Am J Transplant 2011, 11(6):1201-1208.
108. Ison M.G., Hager J., Blumberg E., et al. Donor-derived disease transmission events in the United States: data reviewed by the OPTN/UNOS Disease Transmission Advisory Committee. Am J Transplant 2009, 9(8):1929-1935.
109. Ison M.G., Llata E., Conover C.S., et al. Transmission of human immunodeficiency virus and hepatitis C virus from an organ donor to four transplant recipients. Am J Transplant 2011, 11(6):1218-1225.
110. Seem DL, Lee I, Umscheid GA, etal. Guideline for reducing transmission of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus through organ transplantation. 2011. Available at: Accessed January 2, 2013. http://www.cdc.gov.
111. Yao F., Seed C., Farrugia A., et al. The risk of HIV, HBV, HCV and HTLV infection among musculoskeletal tissue donors in Australia. Am J Transplant 2007, 7(12):2723-2726.
112. Biswas R., Tabor E., Hsia C.C., et al. Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection. Transfusion 2003, 43:788-798.
113. Busch M.P., Glynn S.A., Wright D.J., et al. Relative sensitivities of licensed nucleic acid amplification tests for detection of viremia in early human immunodeficiency virus and hepatitis C virus infection. Transfusion 2005, 45(12):1853-1863.
114. Giachetti C., Linnen J.M., Kolk D.P., et al. Highly sensitive multiplex assay for detection of human immunodeficiency virus type 1 and hepatitis C virus RNA. JClin Microbiol 2002, 40(7):2408-2419.
115. Buell J.F., Beebe T.M., Trofe J., et al. Donor transmitted malignancies. Ann Transplant 2004, 9(1):53-56.
116. Kauffman H.M., McBride M.A., Cherikh W.S., et al. Transplant tumor registry: donor related malignancies. Transplantation 2002, 74(3):358-362.
117. Desai R., Collett D., Watson C.J., et al. Cancer transmission from organ donors-unavoidable but low risk. Transplantation 2012, 94(12):1200-1207.
118. Feng S., Buell J.F., Chari R.S., et al. Tumors and transplantation: the 2003 third annual ASTS State-of-the-Art Winter Symposium. Am J Transplant 2003, 3(12):1481-1487.
119. Collignon F.P., Holland E.C., Feng S. Organ donors with malignant gliomas: an update. Am J Transplant 2004, 4(1):15-21.
120. Finger E.B., Feng S. Central nervous system tumors and organ donation: an update. Curr Opin Organ Transplant 2006, 11(2):146-150.